6 Top Gainers In Pharma Sector (DFFN, QTNT, ORGO...)

(RTTNews) - The following are some of today's top gainers in the pharma/biotech sector.

1. Diffusion Pharmaceuticals Inc. (DFFN)

Diffusion Pharma is a clinical stage biotechnology company developing treatments for life-threatening medical conditions.

Gained 91.56% to close Thursday's (May 2) trading at $5.90.

News: No news

Clinical Trials:

The Company's lead drug candidate is Trans Sodium Crocinate.

A phase III study of Trans Sodium Crocinate to target inoperable glioblastoma multiforme brain cancer, dubbed INTACT, is underway. The Company was given FDA clearance last September to conduct a phase II on-ambulance trial of Trans Sodium Crocinate for the treatment of stroke, named PHAST-TSC.

Cash position:

Diffusion had cash and cash equivalents of $8.0 million as of December 31, 2018. The Company believes its cash and cash equivalents are sufficient to fund operations into July 2019.

2. ARCA biopharma Inc. (ABIO)

ARCA biopharma is a clinical-stage biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases.

The Company's lead product candidate is Gencaro, which is in development for the treatment of atrial fibrillation in certain patients who also have heart failure (HF).

Gained 23.41% to close Thursday's trading at $12.65.

News: No news

Near-term Catalyst:

Gencaro is all set to advance into a phase III trial, dubbed PRECISION-AF, in the fourth quarter of this year.

3. Auris Medical Holding AG (EARS)

Auris Medical is a biopharmaceutical company developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders.

Gained 15.51% to close Thursday's trading at $5.14.

News: No news

Clinical Trials & Near-term Catalysts:

The lead drug candidate is Keyzilen (AM-101) for tinnitus. The Company has completed the design of a new Phase 2/3 trial for Keyzilen program, and intends to discuss and validate the trial design with the FDA and EMA.

Preparations for a phase II proof-of-concept study of AM-125 in acute vertigo, dubbed TRAVERS, and Phase 1b trial with AM-201 in antipsychotic-induced weight gain are progressing.

In addition, Auris Medical has two Phase 3 programs under development: Sonsuvi (AM-111) for acute inner ear hearing loss and Keyzilen (AM-101) for acute inner ear tinnitus.

Recent event:

On May 1, 2019, a 1-for-20 reverse stock split became effective. The reverse stock split was implemented to regain compliance with the $1.00 minimum bid price requirement for continued listing on NASDAQ.

4. Citius Pharmaceuticals Inc. (CTXR)

Gained 14% to close Thursday's trading at $1.14.

News: No news

Pipeline:

A phase III trial of Mino-Lok Therapy in combination with systemic antibiotics in the treatment of catheter-related bloodstream infections enrolled the first patient as recently as February of this year. This trial is planned to enroll 700 patients in 50 participating institutions, all located in the U.S. There will be interim analyses at the 50% and 75% point of the trial as measured by the number of patients treated. Also in the pipeline is CITI-002 to treat hemorrhoids, which is a phase IIb-ready compound.

5. Quotient Limited (QTNT)

Quotient Limited is a commercial-stage diagnostics company, involved in blood grouping and serological disease screening tests.

Gained 12.13% to close Thursday's trading at $8.97.

News: The Company announced receipt of the CE Mark for its initial Immunohematology (IH) Microarray for use with its CE Marked MosaiQ diagnostic platform.

6. Organogenesis Holdings Inc. (ORGO)

Organogenesis is a regenerative medicine company developing products for the advanced wound care, and surgical and sports medicine markets.

Gained 11.91% to close Thursday's trading at $7.89.

News: The Company has received an Innovative Technology contract from Vizient Inc. for its portfolio of advanced wound care and surgical and sports medicine products.

Vizient is a health care performance improvement company, with more than 3,100 hospital and health system members.

Near-term Catalyst:

The Company is slated to report first quarter fiscal year 2019 financial results before the market opens on May 10, 2019.